Cholera - Pipeline Review, H2 2014

Published: Jul, 2014 | Pages: 48 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Cholera - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Cholera - Pipeline Review, H2 2014', provides an overview of the Cholera's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Cholera, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cholera and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Cholera
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Cholera and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Cholera products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Cholera pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Cholera
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cholera Overview 6
Therapeutics Development 7
Pipeline Products for Cholera - Overview 7
Pipeline Products for Cholera - Comparative Analysis 8
Cholera - Therapeutics under Development by Companies 9
Cholera - Therapeutics under Investigation by Universities/Institutes 10
Cholera - Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Cholera - Products under Development by Companies 14
Cholera - Products under Investigation by Universities/Institutes 15
Cholera - Companies Involved in Therapeutics Development 16
Napo Pharmaceuticals, Inc. 16
PaxVax 17
Beijing Minhai Biotechnology Co., Ltd 18
Cholera - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
crofelemer DR - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PXVX-0200 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Trivalent Cholera Vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
AKT-10082 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Cholera - Recent Pipeline Updates 33
Cholera - Dormant Projects 38
Cholera - Discontinued Products 39
Cholera - Product Development Milestones 40
Featured News & Press Releases 40
Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 40
May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 41
Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 41
Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 42
Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 44
Mar 19, 2012: FDA Accepts PaxVax's IND For Single-Dose Oral Cholera Vaccine 44
Aug 26, 2008: Crucell to move Dukoral and rCTB bulk production, formulation and fill/finish activities from Sweden to other sites 45
Mar 23, 2004: IMPAX Receives Final FDA Approval for Generic Version of Declomycin; Fifth ANDA Approval in 2004 45
Feb 25, 2003: Dukoral Approved In Canada 46
Mar 11, 2002: European Marketing Authorisation Application Submitted For Dukoral 46
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Number of Products under Development for Cholera, H2 2014 7
Number of Products under Development for Cholera - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Number of Products under Investigation by Universities/Institutes, H2 2014 10
Comparative Analysis by Late Stage Development, H2 2014 11
Comparative Analysis by Clinical Stage Development, H2 2014 12
Comparative Analysis by Early Stage Development, H2 2014 13
Products under Development by Companies, H2 2014 14
Products under Investigation by Universities/Institutes, H2 2014 15
Cholera - Pipeline by Napo Pharmaceuticals, Inc., H2 2014 16
Cholera - Pipeline by PaxVax, H2 2014 17
Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H2 2014 18
Assessment by Monotherapy Products, H2 2014 19
Number of Products by Stage and Target, H2 2014 21
Number of Products by Stage and Mechanism of Action, H2 2014 23
Number of Products by Stage and Route of Administration, H2 2014 24
Number of Products by Stage and Molecule Type, H2 2014 26
Cholera Therapeutics - Recent Pipeline Updates, H2 2014 33
Cholera - Dormant Projects, H2 2014 38
Cholera - Discontinued Products, H2 2014 39